After graduating from Yamaguchi University, I joined the former Third Department of Internal Medicine. At Yamaguchi University Hospital, Ogori Daiichi Hospital, and Kōsan Central Hospital, I was primarily involved in the management of thyroid disorders, leukemia, malignant lymphoma, pituitary and adrenal diseases, diabetes and metabolic disorders, multiple myeloma, hematopoietic stem cell transplantation, and a wide range of solid tumors requiring systemic chemotherapy. At Yamato Hospital, Saiki Hospital, and Onaka Hospital, I provided care for ischemic heart disease, renal disorders, infectious diseases, heart failure, and cerebral infarction.

At the National Jewish Research and Health Center, I studied the immunological aspects of anticancer agents, bone marrow transplantation, and immune-mediated diseases. I later conducted research at the University of Colorado on mechanisms of chemoresistance and the activation of EGF signaling pathways in cancer cells. During this period, I also developed a novel gene‑delivery device for suspension cells and created multivariate analytical methods capable of quantifying qualitative biological factors. These analytical approaches enabled highly accurate prediction of vascular events such as cerebral and myocardial infarction.

I have also filed a patent application (Japanese Patent Application No. 2018‑009190) for a method to detect gene mutations caused by oxidative stress, a mechanism relevant to certain rare diseases.

Currently, my work focuses on AI‑driven molecular design of anticancer agents, as well as the identification of adverse effects and secondary beneficial actions of existing drugs. I am also engaged in developing new mathematical foundations for protein structural analysis and molecular docking. I continue to practice medicine and conduct research with the conviction that clinical practice and scientific inquiry lie on the same continuum.